Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RPRX |
---|---|---|
09:32 ET | 30592 | 27.24 |
09:34 ET | 14193 | 27.16 |
09:36 ET | 6300 | 27.2 |
09:38 ET | 9036 | 27.18 |
09:39 ET | 3648 | 27.18 |
09:41 ET | 6636 | 27.24 |
09:43 ET | 7125 | 27.26 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Royalty Pharma PLC | 16.3B | 15.3x | +1.83% |
Amneal Pharmaceuticals Inc | 2.1B | -11.7x | --- |
Catalent Inc | 9.9B | -8.5x | --- |
Jazz Pharmaceuticals PLC | 6.7B | 21.6x | -3.53% |
Mallinckrodt PLC | 1.6M | 0.0x | --- |
Roivant Sciences Ltd | 9.1B | 2.2x | --- |
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.3B |
---|---|
Revenue (TTM) | $2.2B |
Shares Outstanding | 597.4M |
Dividend Yield | 3.08% |
Annual Dividend Rate | 0.8400 USD |
Ex-Dividend Date | 05-16-24 |
Pay Date | 06-14-24 |
Beta | 0.46 |
EPS | $1.78 |
Book Value | $14.61 |
P/E Ratio | 15.3x |
Price/Sales (TTM) | 7.3 |
Price/Cash Flow (TTM) | 13.7x |
Operating Margin | 41.96% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.